Researchers have found that patients with stage B heart failure characteristics and type 2 diabetes have impaired functional capacity.

Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.

Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development ...

Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice ...

The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (“ARI”) for the treatment of CNS rare metabolic diseases, including ...

College of Pharmacy, Yeungnam University, Gyeongsan, Gyeongbuk 38541, South Korea College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae, Gyeongnam ...

Dr. Baumgartner joins Applied as an accomplished global drug development leader with over 35 years of experience in senior regulatory, clinical development, and medical affairs roles. He has held a ...

Their primary focus is on govorestat, an Aldose Reductase Inhibitor for CNS rare metabolic diseases. The press release includes forward-looking statements under the Private Securities Litigation ...

Figure 1: Structures of the Fd–FNR complex and PDR. Figure 3: NMR chemical shift perturbation of Fd upon complex formation with FNR. Figure 4: Structural perturbation of FNR induced by complex ...